Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 24, 09:00 – 15:35
In-Vivo CAR-T and Cellular Therapy Session
Stay tuned
09:00-09:05
09:05-09:20 Innovation and Progress of In Vivo CAR-T at Juventas Cell Therapy
Yi Feng:CMO, Juventas Cell Therapy
09:20-09:35 iMagic In Vivo CAR-T – Ushering in a New Era of Cell Therapy
Crystal Sun:Founder, Chairman & CEO, Immunofoco
09:35-09:50 mRNA-tLNP for in Vivo CAR-T: challenge and solution
Siyu Wang:Senior Scientist, Formulation Development, mRNA Division, Pengbo Biotechnology
09:50-10:05 "No Flow Cytometry Without ABclonal" – Comprehensive Flow Cytometry Solutions Empowering In Vivo CAR-T Drug Development
Zack Wu:Founder & CEO, ABclonal
10:05-10:20 Break
10:20-10:35 Recombinant Antibody-Based Flow Cytometry Analysis and Novel Strategies for CAR-T Detection Reagents
Yanan Lu:Director of Recombinant Antibody R&D Department, Proteintech
10:35-10:50 Conjugation Technology-Driven Evolution of In Vivo CAR-T: From Precision Targeting to Regulatory Readiness
James Fang:Founder & CEO, Enorna Biotechnology
10:50-11:05 The Road to In Vivo CAR-T Success: Progress, Challenges, Strategies, and Clinical Translation
Xiaowen He:Co-founder & Chief Scientific Officer, Origincell Therapeutics
11:05-11:20 From Origin to Endpoint: Building the 'Highway' for In Vivo CAR-T Preclinical Research
Fei Tian:R&D Director, MileCell
11:20-11:35 Viral Vectors for In Vivo Gene Delivery: Design, Process Development and Critical Quality Control
Ming-Wei Che:RephImmune Founder & CEO
11:35-11:50 In Vivo CAR-T Gene Delivery Technology Routes and Key Process Development Considerations
Ping Zou:Vice President & Head of Technical Team, WuXi ATU
11:50-12:05 Innovation and Progress of In Vivo CAR-T at IASO Biotherapeutics
Min Zhang:Head of Global Business Development, IASO Biotherapeutics
12:05-12:20 Source Compliance: An Integrated Bioprocessing Platform Empowering In Vivo CAR-T Drug Discovery and Manufacturing
Mars Wang:Director of Product Business Development, Lepure Biotech
12:20-13:30 Lunch Break
13:30-13:50 Proprietary LNP Delivery Technology and In Vivo CAR-T
Siyuan Yin:COO,TheMedium Therapeutics
13:50-14:05 Process Synergies in Cell Therapy: Breakthroughs and Perspectives on In Vivo vs. Ex Vivo Approaches
Lei Xu:Project Lead, Genechem
14:05-14:20 Ab-LNP One-Stop Characterization Services to Accelerate the Industrialization of In Vivo CAR-T
Xingxing Wang:Vice General Manager, Oligonucleotide Business Unit, Synthgene
14:20-14:35 Development Progress of In Vivo TCR-T Therapies Targeting Hepatitis B Virus
Xiaoming Peng:CEO, Lion TCR
14:35-14:50 Next-Generation Humanized Models Empowering In Vivo Cell Therapy: A Focus on Efficacy and Safety Assessment
Xinxin Zhang:Head of Preclinical Innovation & Services, genOway Shanghai
14:50-15:05 In Vivo CAR-Tumor: A Game-Changer in Immuno-Oncology
George Zhou:CEO, Joint Biosciences
15:05-15:20 Toward immune reset: early clinical evidence of allo CAR-T in autoimmune disease
Wengang Ge:VP Clinical Development, Imviva Biotechnologies
15:20-15:35 王文新 Wenxin Wang 聚茵生物创始人、CSO;都柏林大学/安徽理工大学 讲席教授 Founder&CSO, PolyGene Biotech;Chair Professor at University College Dublin / Anhui University of Science and Technology
Wenxin Wang:Founder&CSO, PolyGene Biotech;Chair Professor at University College Dublin / Anhui University of Science and Technology